204 related articles for article (PubMed ID: 7194062)
1. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
Vorberg G; Ziegler WJ
Arzneimittelforschung; 1980; 30(11b):2068-72. PubMed ID: 7194062
[TBL] [Abstract][Full Text] [Related]
2. [Clinical effects and tolerance of etofylline clofibrate].
Ziegler WJ; Metz G; Specker M
Arzneimittelforschung; 1980; 30(11b):2053-8. PubMed ID: 7194059
[TBL] [Abstract][Full Text] [Related]
3. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
[TBL] [Abstract][Full Text] [Related]
4. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H
Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].
Sterner W; Chibanguza G; Metz G
Arzneimittelforschung; 1980; 30(11b):2038-41. PubMed ID: 7194056
[TBL] [Abstract][Full Text] [Related]
6. [Etofylline clofibrate in the treatment of diabetic dyslipidemia: results of a 6-month period of therapy].
Rajecová E; Klimes I; Seböková E; Rychnavská E; Pleváková L; Linke-Cvrkalová A; Langrová H
Vnitr Lek; 1995 Oct; 41(10):677-81. PubMed ID: 8578698
[TBL] [Abstract][Full Text] [Related]
7. [On the uricosuric activity of etofylline clofibrate (author's transl)].
Ziegler WJ
Arzneimittelforschung; 1980; 30(11b):2073-4. PubMed ID: 7194063
[TBL] [Abstract][Full Text] [Related]
8. Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats.
Ginocchio AV; Metz G
Arzneimittelforschung; 1980; 30(11b):2032-4. PubMed ID: 7194054
[TBL] [Abstract][Full Text] [Related]
9. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Noseda G; Fragiacomo C; Weidmann P; Bachmann C
Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
[TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutic evaluation of etofylline clofibrate and its drug formulation.
Ritschel WA; Thompson GA; Lücker PW; Wetzelsberger K
Arzneimittelforschung; 1980; 30(11b):2020-3. PubMed ID: 7194052
[TBL] [Abstract][Full Text] [Related]
11. [Use of etofyllinclofibrate (Duolip Forte) in combined hyperlipidemia].
Hrebícek J; Skottová N; Chmela Z; Hrbková M
Cas Lek Cesk; 1995 Mar; 134(5):141-4. PubMed ID: 7728839
[TBL] [Abstract][Full Text] [Related]
12. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
Bolzano K; Krempler F; Schellenberg B; Schlierf G
Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
[TBL] [Abstract][Full Text] [Related]
13. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the hypolipaemic activity of etofylline clofibrate, a new ester of etofylline and clofibric acid, and comparison with effects of known hypolipaemic agents.
Davies JE; Kellett DN
Arzneimittelforschung; 1980; 30(11b):2035-7. PubMed ID: 7194055
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
Schwartzkopff W; Schilling A; Calder D
Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415
[No Abstract] [Full Text] [Related]
16. [Treatment of various types of hyperlipoproteinaemia with a combination of Mg-chlorophenoxy-isobutyrate and mesoinositol-hexanicotinate (author's transl)].
Bolzano K; Krempler F; Haslauer F
Arzneimittelforschung; 1979; 29(10):1621-4. PubMed ID: 583231
[TBL] [Abstract][Full Text] [Related]
17. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
Lageder H
Wien Klin Wochenschr; 1980 Feb; 92(3):95-101. PubMed ID: 6985560
[TBL] [Abstract][Full Text] [Related]
18. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Kaffarnik H; Schneider J; Schubotz R; Zöfel P; Hausmann L; Goebel KM
Artery; 1980; 8(6):537-46. PubMed ID: 6114725
[TBL] [Abstract][Full Text] [Related]
20. [Chemistry of phenoxyacetic acid esters of oxyalkyltheophyllines and 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methyl-propionate] (etofylline clofibrate), a novel antilipaemic agent (author's transl)].
Metz G; Specker M
Arzneimittelforschung; 1980; 30(11b):2014-9. PubMed ID: 7194051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
